Drug-Induced Lipid Changes

A. Mantel‐Teeuwisse,Judith M.E. Kloosterman,A. M. Zee,O. Klungel,A. Porsius,A. Boer

DOI: https://doi.org/10.2165/00002018-200124060-00003

Drug Safety

Abstract:

What problem does this paper attempt to address?

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Jie Dong,Xu Wang,Yu,Xu Yan,Jiu-Wei Cui

DOI: https://doi.org/10.4103/0366-6999.238141

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:Background: Base excision repair (BER) plays an important role in the maintenance of genome integrity and anticancer drug resistance. This study aimed to explore the role of BER gene polymorphisms in response to chemotherapy for advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Methods: During the period from November 2009 to January 2016, a total of 152 patients diagnosed with NSCLC Stage IIIB and IV in the First Hospital of Jilin University were admitted into this study. The XRCC1 G28152A, MUTYH G972C, HOGG1 C1245G, and PARP1 T2444C polymorphisms of all the patients were detected by mass spectrometry. The logistic regression was used for statictical analysis. All tests were bilateral test, and a P < 0.05 was considered statistically significant. Results: The logistic regression model showed that the response rate of chemotherapy of the PARP1 T2444C polymorphisms, CC genotype (odds ratio [OR]: 5.216, 95% confidence interval [CI]: 1.568–17.352, P = 0.007), TC genotype (OR: 2.692, 95% CI: 1.007–7.198, P = 0.048), as well as the genotype of TC together with CC (OR: 3.178, 95% CI: 1.229–8.219, P = 0.017) were significantly higher than those of TT wild type. There was no relationship between the MUTYH G972C, XRCC1 G28152A, and HOGG1 C1245G gene polymorphisms and chemosensitivity. Conclusions: The PARP1 2444 mutation allele C might be associated with the decreased sensitivity to platinum-based chemotherapy in advanced NSCLC. These findings may be helpful in designing individualized cancer treatment.
Nucleotide Excision Repair Gene ERCC1 19007T>C Polymorphism Contributes to Lung Cancer Susceptibility: A Meta-Analysis

Fuyi Xie,Qi Sun,Shengjun Wu,Xinyou Xie,Zhiwei Liu

DOI: https://doi.org/10.1089/gtmb.2013.0329

IF: 1.736

2014-01-01

Genetic Testing and Molecular Biomarkers

Abstract:Aims: Association studies of ERCC1 19007T > C polymorphism and lung cancer have yielded inconsistent results, possibly because single studies often lack sufficient statistical power. Methods: We examined the association by performing a meta-analysis. Two investigators independently searched the Google Scholar, PubMed, and CNKI Databases. Summary odds ratios (ORs) and 95% confidence intervals (95% CIs) for 19007T > C polymorphism and lung cancer were calculated in a fixed-effects model and a random-effects model, when appropriate. Publication bias was evaluated using Begg's funnel plot. Results: Overall, the meta-analysis included 7 case-control studies for each polymorphism with 3840 confirmed lung cancer cases and 4712 healthy controls in total. Meta-analysis results showed a significant association between 19007T > C polymorphism and lung cancer risk (CC vs. TT: OR=0.72, 95% CI 0.53-0.99; CT vs. TT: OR=0.84, 95% CI 0.73-0.98; Dominant model: OR= 0.70, 95% CI 0.52-0.95). Further stratified analyses conducted by ethnicity reveal a statistically significant association in Asians (Dominant model: OR= 0.63, 95% CI 0.43-0.93), but no significant association in Europeans. Conclusions: This meta-analysis suggests that the ERCC1 19007T > C polymorphism may be associated with lung cancer risk in Asians, while larger scale association studies are necessary to further validate the association of 19007T > C polymorphism with lung cancer risk.
Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.

Jing Dong,Zhibin Hu,Yongqian Shu,Shiyang Pan,Wenping Chen,Yi Wang,Lingmin Hu,Yue Jiang,Juncheng Dai,Hongxia Ma,Guangfu Jin,Hongbing Shen

DOI: https://doi.org/10.1002/mc.20819

2012-01-01

Molecular Carcinogenesis

Abstract:To assess systematically whether potentially functional polymorphisms in DNA repair genes influence the clinical behavior of non-small-cell lung cancer (NSCLC), we examined the impact of a comprehensive panel of 218 signal nucleotide polymorphisms (SNP) in 50 candidate DNA repair genes on overall survival of NSCLC in a case-cohort of 568 lung cancer patients. SNPs associated with lung cancer prognosis primarily mapped to 14 genes in different repair pathways, and 6 SNPs were remained in the final model after multivariate stepwise Cox regression analysis: ATM rs189037; MRE11A rs11020802; ERCC2 rs1799793; MBD4 rs140693; XRCC1 rs25487, and PMS1 rs5742933. In the combined analysis of these 6 SNPs, an increasing number of unfavorable loci was associated with a poorer prognosis (P for trend: <0.0001) and patients having 24 unfavorable loci had a 1.99-fold elevated risk of death 95% confidence interval (CI)?=?1.582.50, compared with those carrying 01 unfavorable loci, and this elevated risk was more evident among stages III patients (hazard ratio?=?3.04, 95% CI?=?1.864.98, P for heterogeneity: 0.07). Furthermore, a significant effect of SNPs in nucleotide excision repair pathway on lung cancer survival was observed among 185 stages IIIIV patients treated with platinum-based chemotherapy without surgical operation: XPC rs2228000 (Ala499Val; P?=?0.002) and ERCC1 rs11615 (Asn118Asn; P?=?0.012). Our data indicate that potentially functional polymorphisms in DNA repair genes may serve as candidate prognostic markers of clinical outcome of NSCLC. (c) 2011 Wiley Periodicals, Inc.
Effect of ERCC2 rs13181 and rs1799793 polymorphisms and environmental factors on the prognosis of patients with lung cancer

Haorui Zhang,Yutao Li,Shicheng Guo,Yi Wang,Haijian Wang,Daru Lu,Jiucun Wang,Li Jin,Gengxi Jiang,Junjie Wu,Yiping Han,Juhong Li

2020-10-15

Abstract:Purpose: The 5-year survival rate of patients with lung cancer in China is < 20%, and predicting their prognosis is difficult. Here, we investigated the association between two common non-synonymous single-nucleotide polymorphisms (SNPs) in the excision repair cross-complementing 2 (ERCC2) genes (rs13181 and rs1799793) and the prognosis of patients with lung cancer. Methods: Genomic DNA was extracted from the blood samples of 839 patients with lung cancer and genotyped using the SNPscan technique. The association between patient prognosis and the ERCC2 genotype was analyzed using a multivariate Cox proportional hazards model adjusted for multiple potential confounders. Results: The presence of ERCC2 rs13181 T>G significantly increased the risk of death (adjust hazard ratio (HR) = 1.29, 95% CI: 1.06-1.56, P = 0.009). Patients with the rs13181 TG genotype (adjust HR = 1.34, 95% CI: 1.08-1.65, P = 0.007) and rs13181 dominant mode TG+GG (adjust HR = 1.33, 95% CI: 1.08-1.63, P = 0.007) had significantly worse overall survival. Moreover, stratified analyses showed that patients with the TG and TG+GG rs13181 genotypes who were male, elderly (≥60 years), had a history of smoking, or without family history of malignant tumors had a significantly increased risk of death. In patients with adenocarcinoma lung cancer (ADC), the rs1799793 genotype CT (adjust HR = 1.49, 95% CI: 1.06-2.09, P = 0.023) and dominant model CT+TT (adjust HR = 1.45, 95% CI = 1.04-2.02, P = 0.027) were associated with an increased risk of death. Conclusion: ERCC2 rs13181 and rs1799793 SNPs may be significant prognostic factors for the risk of death among patients with lung cancer.
Genetic Variants in ERCC1 and XPC Predict Survival Outcome of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Therapy

Ruoxin Zhang,Ming Jia,Huijing Xue,Yuan Xu,Mengyun Wang,Meiling Zhu,Menghong Sun,Jianhua Chang,Qingyi Wei

DOI: https://doi.org/10.1038/s41598-017-10800-5

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Nucleotide excision repair (NER) plays a vital role in platinum-induced DNA damage during chemotherapy. We hypothesize that regulatory single nucleotide polymorphisms (rSNPs) of the core NER genes modulate clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy (PBS). We investigated associations of 25 rSNPs in eight NER genes with progression free survival (PFS) and overall survival (OS) in 710 NSCLC patients. We found that ERCC1 rs3212924 AG/GG and XPC rs2229090 GC/CC genotypes were associated with patients’ PFS (HRadj = 1.21, 95% CI = 1.03–1.43, P adj = 0.021 for ERCC1 and HRadj = 0.80, 95% CI = 0.68–0.94, P adj = 0.007 for XPC), compared with the AA and GG genotypes, respectively. The association of XPC rs2229090 was more apparent in adenocarcinoma than in squamous cell carcinoma patients. Additionally, ERCC4 rs1799798 GA/AA genotypes were associated with poorer OS (HRadj = 1.32, 95% CI = 1.04–1.69, P adj = 0.026), compared with the GG genotype. The expression quantitative trait loci analysis revealed that ERCC1 rs3212924 and XPC rs2229090 might regulate transcription of their genes, which is consistent with their associations with survival. Larger studies are needed to validate our findings with further functional studies to elucidate the mechanisms underlying these observed associations.
Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population.

Jing Dong,Juncheng Dai,Yongqian Shu,Shiyang Pan,Lin Xu,Wenping Chen,Yi Wang,Guangfu Jin,Hongxia Ma,Mingfeng Zhang,Zhibin Hu,Hongbing Shen

DOI: https://doi.org/10.1093/carcin/bgq079

2010-01-01

Carcinogenesis

Abstract:Over the last decades, combined chemotherapies that inhibit different signalling pathways together have been demonstrated to be more effective to treat the non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) and the vascular endothelium growth factor (VEGF) are two key targets. Polymorphisms in EGFR and VEGF genes have been identified to be associated with therapy-response and cancer survival. In this study, we hypothesized that single-nucleotide polymorphisms (SNPs) of EGFR and VEGF genes are associated with NSCLC patients' survival in Chinese. Therefore, we screened and genotyped 54 potentially functional SNPs as well as tagging SNPs in these two genes using Illumina Golden Gate platform in 568 NSCLC patients. We found that subjects carrying EGFR rs3735061AA and rs6958497AG/GG genotypes survived significantly shorter time [median survival time (MST): 22.2 and 19.4 months, respectively] than those carrying rs3735061AG/GG (MST: 25.1 months) and rs6958497AA (MST: 25.9 months) (log-rank P = 0.015 for rs3735061 and log-rank P = 0.028 for rs6958497). However, subjects carrying EGFR rs759165AG/AA genotypes survived significantly longer (MST: 38.7 months) than those carrying rs759165GG genotype (MST: 24.7 months) (log-rank P = 0.024). Multivariate Cox regression analyses showed that the genotypes of rs3735061AA and rs6958497AG/GG were associated with a significantly increased risk of death for NSCLC [hazard ratio (HR) = 2.82, 95% confidence interval (CI) = 1.66-4.78 for rs3735061AA and HR = 1.69, 95% CI = 1.26-2.28 for rs6958497AG/GG], whereas the rs759165AG/AA were associated with a 44% significantly decreased risk of death of NSCLC (HR = 0.56, 95% CI = 0.39-0.83). Stepwise COX regression analyses suggested that EGFR rs373506, rs759165 and rs6958497 may be independent candidate biomarkers to predict NSCLC survival in this population.
Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression.

Lei Cheng,Lixin Qiu,Mengyun Wang,Ruoxin Zhang,Menghong Sun,Xiaodong Zhu,Yanong Wang,Qingyi Wei

DOI: https://doi.org/10.1002/mc.22713

2017-01-01

Molecular Carcinogenesis

Abstract:DNA repair protects genomic integrity and may modulate chemotherapy efficacy. Few large-scale studies have evaluated predictive roles of genetic variants of DNA repair genes in survival of Chinese gastric cancer (GCa) patients treated with chemotherapy. Here, we assessed the roles of 35 single nucleotide polymorphisms (SNPs) in DNA repair genes in survival of 1002 GCa patients, of whom 694 received chemotherapy and 308 did not. Among patients receiving chemotherapy, the ERCC1 rs2298881A allele was associated with a better survival [hazards ratio (HR)=0.82, 95% confidence interval (CI)=0.69-0.98; P=0.03], whereas two XRCC4 SNPs were associated with a worse survival (HR=1.26, 95% CI=1.03-1.54 for the rs10040363G allele, P=0.02; and HR=1.30, 95% CI=1.06-1.59 for the rs2075685T allele, P=0.01). These three SNPs were unique survival predictors for patients treated with chemotherapy (P<0.05 for all) but not for patients without chemotherapy (P>0.05 for all), suggesting that they modulated chemotherapy efficacy. Patients who received chemotherapy and had haplotypes with at least one death-risk allele in XRCC4 had a poor survival, and the trend for an increase in the number of death-risk alleles adversely affecting the survival was also observed in an allelic dose-dependent manner (P-trend=0.001). Further functional analysis revealed that the death-risk alleles up-regulated the gene expression, leading to a worse survival as suggested by our meta-analysis pooling both mRNA microarray data from the GEO database and published data (ERCC1: HR=1.31 [1.08-1.58]; P=0.006). These functional genetic variants may independently or jointly affect survival in chemotherapy-treated GCa patients by modulating the gene expression in the tumors.
Association of ERCC1-C118T and -C8092A Polymorphisms with Lung Cancer Risk and Survival of Advanced-Stage Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: a Pooled Analysis Based on 39 Reports.

Tong-Peng Xu,Hua Shen,Ling-Xiang Liu,Yong-Qian Shu

DOI: https://doi.org/10.1016/j.gene.2013.05.021

IF: 3.913

2013-01-01

Gene

Abstract:The published data on the predictive role of ERCC1 polymorphisms in lung cancer risk and survival of patients with advanced non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy remains inconsistent. The aim of this meta-analysis was to determine the role of ERCC1 gene polymorphisms (C118T and C8092A) in this clinical situation. Eligible studies were included and assessed for quality using multiple search strategies. Thirty-nine published papers involving 9615 cases (4606 with Stage III/IV disease) and 5542 controls were included in the analysis. Pooled odds ratios (OR) or hazard ratios (HR) with 95% confidence intervals (CI) were used to estimate risk. ERCC1-C118T was associated with lung cancer risk. The OR was 0.90 (95% CI: 0.81-0.99, p=0.043) in an additive genetic model (C allele vs. T allele) and 0.77 (95% CI: 0.63-0.95, p=0.013) in a recessive genetic model (CC/CT vs. TT). The corresponding risk was 0.74 (95% CI: 0.58-0.94, p=0.013) based on a homozygous comparison (CC vs. TT). No significant correlation was found for ERCC1 C8092A and there was no obvious relationship between ERCC1 C118T/C8092A polymorphisms and objective response to platinum-based chemotherapy. Overall survival (OS) of patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy was significantly related to ERCC1 C118T (HR: 1.29, 95% CI: 1.07-1.56, p=0.007, CT/TT vs. CC). There was no relationship between ERCC1 C8092A and survival (HR: 1.32, 95% CI: 0.84-2.10, p=0.23, CA/AA vs. CC). These findings suggest that ERCC1 C118T polymorphisms may serve as a biomarker for lung cancer risk and have prognostic value in patients with advanced non-small cell lung cancer (NSCLC) undergoing platinum-based treatment. Further studies with larger numbers of subjects from a worldwide arena are needed to validate the associations.
Single nucleotide polymorphisms in XRCC1,XPD and platinum prognosis in non-small-cell lung cancer patients

LIU Xin-zi,QIAN Xiao-ping,LIU Bao-rui,HU Wen-jing,WANG Li-feng,WEI Jia,YU Li-Xia

DOI: https://doi.org/10.3969/j.issn.1672-2353.2008.09.002

2008-01-01

Abstract:Objective XPD and XRCC1 are emerging as essential elements in repair of pla- timun-DNA adducts.To investigate whether the single nucleotide polymorphism (SNP) in DNA re- pair gene XRCC1 (X-ray repair cross-complementing 1) and XPD are associated with the clinical prognosis of platinum-containing combination chemotherapy in the paraffin-embedded tissue of non- small-cell lung cancer.Methods XRCC1 and XPD genotypes were assessed using 5' nuclease allelic discrimination assay (TaqMan) by real-time PCR.The pathological parameters and survival data were evaluated according to the different genotypes in 53 NSCLC.Results The median survival time of patients with Arg/Arg or Arg/Gln genotypes was 24 months compared with 8.0 months of others (P=0.02).No significant association was found between XPD 751 SNP and survival (P>0.05).When we compared combinations of variant alleles across both polymorphisms,we found that a greater number of variant alleles were associated with decreasingoverall survival (P=0.015, log-rank test).In Cox ratio hazard models,XRCC1 Arg399Gln could independently predict overall survival time of lung cancer(P=0.011).Conclusions It suggested that XRCC1 399 SNP might be prognostic marker of survival for lung cancer patients receiving platinum-based chemotherapy. The two polymorphism of XRCC1 and XPD might have synergic effect on the prognosis of platinum agents.
Genetic Variants in Nucleotide Excision Repair Pathway Predict Survival of Esophageal Squamous Cell Cancer Patients Receiving Platinum‐based Chemotherapy

Ruoxin Zhang,Fei Zhou,Lei Cheng,Alexandria Yu,Meiling Zhu,Mengyun Wang,Zhuanxu Zhang,Jiaqing Xiang,Qingyi Wei

DOI: https://doi.org/10.1002/mc.22877

2018-01-01

Molecular Carcinogenesis

Abstract:The benefits of platinum-based chemotherapy (PBC) on survival of esophageal squamous cell carcinoma (ESCC) patients are inexplicit due to the varied therapeutic effects. Nucleotide excision repair (NER) pathway plays a vital role in removing platinum-DNA adducts in tumor cells and hence may modulate the therapeutic effect and survival outcome. The present study assessed the associations of 26 potentially functional regulatory single nucleotide polymorphisms (rSNPs) in nine core NER genes with disease-free survival (DFS) and overall survival (OS) in 339 ESCC patients. We found that ERCC2 rs2097215 T and rs3916788 A, ERCC5 rs3759497 A and XPC rs3731054 C alleles were associated with unfavorable DFS. Patients carrying high-risk allele group (HRG, 5-8 risk alleles) had a significantly shorter DFS, compared with those carrying low-risk alleles (LRG, 0-4 risk alleles) [adjusted hazards ratio (HRadj)=1.64, 95%CI=1.23-2.19, P-adj<0.001]. Three of these SNPs (ie, ERCC2 rs2097215 T and rs3916788 A and ERCC5 rs3759497 A) were also significantly associated with a poorer OS (HRG vs LRG: HRadj=1.75, 95%CI=1.23-2.47, P-adj=0.002). The expression quantitative trait loci (eQTL) analysis revealed significant genotype-expression correlations for ERCC5 rs3759497 and ERCC2 2097215 and rs3916788, which suggest regulatory roles of these SNPs. It appears that these NER variants may independently or jointly exert an impact on survival outcome of Chinese ESCC patients undergoing adjuvant platinum-based therapy. Large studies are warranted to validate these findings.
Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients with Lung Cancer

Jun-Yan Liu,Ting Zou,Ji-Ye Yin,Zhan Wang,Chong Liu,Han-Xue Huang,Fei-Xiang Ding,Meng-Rong Lei,Ying Wang,Min Liu,Zhao-Qian Liu,Li-Ming Tan,Juan Chen

DOI: https://doi.org/10.3389/fphar.2022.915822

IF: 5.6

2022-01-01

Frontiers in Pharmacology

Abstract:Objective: The purpose of this study was to investigate the associations of genetic variants in double-strand break (DSB) repair pathway genes with prognosis in patients with lung cancer treated with platinum-based chemotherapy.Methods: Three hundred ninety-nine patients with lung cancer who received platinum-based chemotherapy for at least two cycles were included in this study. A total of 35 single nucleotide polymorphisms (SNPs) in DSB repair, base excision repair (BER), and nucleotide excision repair (NER) repair pathway genes were genotyped, and were used to evaluate the overall survival (OS) and the progression-free survival (PFS) of patients who received platinum-based chemotherapy using Cox proportional hazard models.Results: The PFS of patients who carried the MAD2L2 rs746218 GG genotype was shorter than that in patients with the AG or AA genotypes (recessive model: p = 0.039, OR = 5.31, 95% CI = 1.09-25.93). Patients with the TT or GT genotypes of TNFRSF1A rs4149570 had shorter OS times than those with the GG genotype (dominant model: p = 0.030, OR = 0.57, 95% CI = 0.34-0.95). We also investigated the influence of age, gender, histology, smoking, stage, and metastasis in association between SNPs and OS or PFS in patients with lung cancer. DNA repair gene SNPs were significantly associated with PFS and OS in the subgroup analyses.Conclusion: Our study showed that variants in MAD2L2 rs746218 and TNFRSF1A rs4149570 were associated with shorter PFS or OS in patients with lung cancer who received platinum-based chemotherapy. These variants may be novel biomarkers for the prediction of prognosis of patients with lung cancer who receive platinum-based chemotherapy.
Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

Xiao Song,Shiming Wang,Xuan Hong,Xiaoying Li,Xueying Zhao,Cong Huai,Hongyan Chen,Zhiqiang Gao,Ji Qian,Jiucun Wang,Baohui Han,Chunxue Bai,Qiang Li,Junjie Wu,Daru Lu

DOI: https://doi.org/10.1038/s41598-017-08257-7

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Nucleotide excision repair (NER) pathway plays critical roles in repairing DNA disorders caused by platinum. To comprehensively understand the association between variants of NER and clinical outcomes of platinum-based chemotherapy, 173 SNPs in 27 genes were selected to evaluate association with toxicities and efficiency in 1004 patients with advanced non-small cell lung cancer. The results showed that consecutive significant signals were observed in XPA, RPA1, POLD1, POLD3 . Further subgroup analysis showed that GTF2H4 presented consecutive significant signals in clinical benefit among adenocarcimoma. In squamous cell carcinoma, rs4150558, rs2290280, rs8067195 were significantly associated with anemia, rs3786136 was significantly related to thrombocytopenia, ERCC5 presented consecutive significant signals in response rate. In patients receiving TP regimen, significant association presented in neutropenia, thrombocytopenia and gastrointestinal toxicity. Association with anemia and neutropenia were found in GP regimen. rs4150558 showed significant association with anemia in NP regimen. In patients > 58, ERCC5 showed consecutive significant signals in gastrointestinal toxicity. Survival analysis showed SNPs in POLD2 , XPA , ERCC6 and POLE were significantly associated with progression free survival, SNPs in GTF2H4 , ERCC6 , GTF2HA , MAT1 , POLD1 were significantly associated with overall survival. This study suggests SNPs in NER pathway could be potential predictors for clinical outcomes of platinum-based chemotherapy among NSCLC.
Data from Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

Lingmin Hu,Chen Wu,Xueying Zhao,Rebecca Heist,Li Su,Yang Zhao,Baohui Han,Songyu Cao,Minjie Chu,Juncheng Dai,Jing Dong,Yongqian Shu,Lin Xu,Yijiang Chen,Yi Wang,Feng Lu,Yue Jiang,Dianke Yu,Hongyan Chen,Wen Tan,Hongxia Ma,Jiaping Chen,Guangfu Jin,Tangchun Wu,Daru Lu,David C. Christiani,Dongxin Lin,Zhibin Hu,Hongbing Shen

DOI: https://doi.org/10.1158/1078-0432.ccr-12-1202

IF: 13.801

2012-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: Genetic variation may influence chemotherapy response and overall survival in cancer patients. Experimental design: We conducted a genome-wide scan in 535 advanced-stage non–small cell lung cancer (NSCLC) patients from two independent cohorts (307 from Nanjing and 228 from Beijing). A replication was carried out on an independent cohort of 340 patients from Southeastern China followed by a second validation on 409 patients from the Massachusetts General Hospital (Boston, MA). Results: Consistent associations with NSCLC survival were identified for five single-nucleotide polymorphisms (SNP) in Chinese populations with P values ranging from 3.63 × 10−5 to 4.19 × 10−7 in the additive genetic model. The minor allele of three SNPs (rs7629386 at 3p22.1, rs969088 at 5p14.1, and rs3850370 at 14q24.3) were associated with worse NSCLC survival while 2 (rs41997 at 7q31.31 and rs12000445 at 9p21.3) were associated with better NSCLC survival. In addition, rs7629386 at 3p22.1 (CTNNB1) and rs3850370 at 14q24.3 (SNW1-ALKBH1-NRXN3) were further replicated in the Caucasian population. Conclusion: In this three-stage genome-wide association studies, we identified five SNPs as markers for survival of advanced-stage NSCLC patients treated with first-line platinum-based chemotherapy in Chinese Han populations. Two of these SNPs, rs7629386 and rs3850370, could also be markers for survival among Caucasian patients. Clin Cancer Res; 18(19); 5507–14. ©2012 AACR.
Polymorphisms in the XRCC1 Gene Modify Survival of Bladder Cancer Patients Treated with Chemotherapy.

Carlotta Sacerdote,Simonetta Guarrera,Fulvio Ricceri,Barbara Pardini,Silvia Polidoro,Alessandra Allione,Rossana Critelli,Alessia Russo,Angeline S. Andrew,Yuanqing Ye,Xifeng Wu,Lambertus A. Kiemeney,Andrea Bosio,Giovanni Casetta,Giuseppina Cucchiarale,Paolo Destefanis,Paolo Gontero,Luigi Rolle,Andrea Zitella,Dario Fontana,Paolo Vineis,Giuseppe Matullo

DOI: https://doi.org/10.1002/ijc.28186

2013-01-01

International Journal of Cancer

Abstract:Survival of bladder cancer patients depends on several factors including disease stage and grade at diagnosis, age, health status of the patient and the applied treatment. Several studies investigated the role of DNA repair genetic variants in cancer susceptibility, but only few studies investigated their role in survival and response to chemotherapy for bladder cancer. We genotyped 28 single nucleotide polymorphisms (SNP) in DNA repair genes in 456 bladder cancer patients, reconstructed haplotypes and calculated a score for combinations of the SNPs. We estimated Hazard Ratios (adjHR) for time to death. Among patients treated with chemotherapy, variant alleles of five SNPs in the XRCC1 gene conferred better survival (rs915927 adjHR 0.55 (95%CI 0.32–0.94); rs76507 adjHR 0.48 (95%CI 0.27–0.84); rs2854501 adjHR 0.25 (95%CI 0.12–0.52); rs2854509 adjHR 0.21 (95%CI 0.09–0.46); rs3213255 adjHR 0.46 (95%CI 0.26–0.80). In this group of patients, an increasing number of variant alleles in a XRCC1 gene score were associated with a better survival (26% decrease of risk of death for each additional variant allele in XRCC1). By functional analyses we demonstrated that the previous XRCC1 SNPs confer lower DNA repair capacity. This may support the hypothesis that survival in these patients may be modulated by the different DNA repair capacity determined by genetic variants. Chemotherapy treated cancer patients bearing an increasing number of “risky” alleles in XRCC1 gene had a better survival, suggesting that a proficient DNA repair may result in resistance to therapy and shorter survival. This finding may have clinical implications for the choice of therapy.
Single Nucleotide Polymorphism in ERCC1 118C→T Predicts the Outcome of NSCLC Patients Receiving Platinum-Based Chemotherapy

QIAN Xiaoping,LIU Baorui,YAN Wenyue,WANG Lifeng,WEI Jia,XIE Li,HU Jing,LIU Xinzi,YU Lixia

DOI: https://doi.org/10.3969/j.issn.1672-4992.2011.10.28

2011-01-01

Journal of Modern Oncology

Abstract:Objective:ERCC1 is emerging as essential elements in repairing platimun-DNA adducts.The aim of this study is to investigate whether the single nucleotide polymorphism(SNP) in Excision repair cross-complementation group 1(ERCC1) 118C→T is associated with the clinical prognosis of platinum-based chemotherapy in non-small-cell lung cancer.Methods: SNP of ERCC1 118C→T was genotyped by PCR-restrictive fragment length polymorphism(PCR-RFLP).The pathological parameters and survival data were evaluated according to the different genotypes in 47 NSCLC patients.Results: ERCC1 118C→T was not related to clinic pathological parameters in NSCLC(P0.05).The median survival of patients with C/C genotypes was 25.0 months compared to 10.5 months of C/T or T/T genotypes(P=0.012).In Cox regresssion models,ERCC1 118C→T was significantly associated with overall survival time of NSCLC patients(P=0.015).Conclusion: ERCC1 codon118 SNP might be a predictive marker of survival for NSCLC patients receiving platinum-based chemotherapy.
Abstract 1350: Genetic Variations in Apoptosis Pathway Are Associated with Survival in Late Stage Non-Small Cell Lung Cancer.

Xiang Shu,Charles Lu,Joe Y. Chang,Jack A. Roth,Xifeng Wu

DOI: https://doi.org/10.1158/1538-7445.am2013-1350

IF: 11.2

2013-01-01

Cancer Research

Abstract:Abstract Dysregulation of apoptosis pathway plays an essential role in carcinogenesis, tumor progression, and resistance to chemotherapy. We hypothesized that genetic variations in genes involved in the apoptosis pathway may affect the survival in late stage non-small cell lung cancer (NSCLC) patients. To test this hypothesis, we genotyped 583 tagging SNPs in 598 late stage NSCLC patients and analyzed their associations with survival individually and jointly. Seven SNPs were statistically significantly associated with overall survival after correction for multiple comparisons (q<0.1). The most significant SNP was rs17592236 on FOXO1 gene under the dominant model (OR: 2.54, 95%CI: 1.71-3.78, p=4.15x10−6). We also observed a significant cumulative effect. Compared to the reference group (patients with no more than two risk alleles), those having five or more risk alleles were much more likely to die within seven months (HR: 3.58, 95% CI: 2.55-5.04, p<0.001). Notably, the median survival time (MST) was significantly reduced by up to 15 months in high risk patients when compared to the reference group (MST: 22.2 months, p<0.001). Survival tree analysis revealed potential higher order gene-gene interactions among these SNPs. Our results provided evidence that genetic variations in the apoptosis pathway modulate NSCLC survival and may serve as biomarkers to differentiate NSCLC patients with different prognosis. Citation Format: Xiang Shu, Charles Lu, Joe Y. Chang, Jack A. Roth, Xifeng Wu. Genetic variations in apoptosis pathway are associated with survival in late stage non-small cell lung cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1350. doi:10.1158/1538-7445.AM2013-1350
Association of variations in platinum resistance-related genes and prognosis in lung cancer patients

Yuan-Kang Zhou,Xiang-Ping Li,Ji-Ye Yin,Ting Zou,Zhan Wang,Ying Wang,Lei Cao,Juan Chen,Zhao-Qian Liu

DOI: https://doi.org/10.7150/jca.44410

2020-04-27

Abstract:Purpose: We aimed to investigate the association of single-nucleotide polymorphisms (SNPs) in HMGB1, REV3L, and NFE2L2 with prognosis in lung cancer patients with platinum-based chemotherapy. Methods: We have recruited 348 lung cancer patients treated with platinum. Log-rank test and Cox regression analysis were used to assess overall survival (OS) and progression-free survival (PFS) among SNP genotypes. Results: The results revealed that patients carrying TC or CC genotype in REV3L rs462779 (HR=0.67, 95% CI=0.51-0.90, P=0.007) and AG or GG genotype in HMGB1 rs1045411 (HR=0.61, 95% CI=0.38-0.99, P=0.046) had a better overall survival. Additionally, carrying TC or TT genotype in rs462779 had a lower risk (OR=0.38, 95% CI=0.17-0.89, P=0.025) of lymph node metastasis, carrying AG or AA genotype in rs1045411 was significantly related to early T stage (OR=0.47, 95% CI=0.29-0.76, P=0.002). In stratified analysis, patients with TC or CC genotype in rs462779 were significantly associated with overall survival in male patients, never-smokers, patients with younger age (≤56), no family history of cancer, adenocarcinoma, advanced stage (stage III or IV), or ECOG PS 0-1. While patients with AG or GG genotype in rs1045411 were significantly associated with overall survival in patients with advanced stage (stage III or IV) or ECOG PS 0-1. Conclusion: Our results indicate that the TC or CC genotype in rs462779 and AG or GG genotype in rs1045411 are contributed to better overall survival. The REV3L rs462779 and HMGB1 rs1045411 may serve as prognosis markers in lung cancer patients with platinum-based chemotherapy.
Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Ting Zou,Jun-Yan Liu,Qun Qin,Jie Guo,Wen-Zhi Zhou,Xiang-Ping Li,Hong-Hao Zhou,Juan Chen,Zhao-Qian Liu

DOI: https://doi.org/10.3390/biomedicines11123133

IF: 4.757

2023-11-25

Biomedicines

Abstract:Background: Lung cancer is still the most lethal malignancy in the world, according to the report of Cancer Statistics in 2021. Platinum-based chemotherapy combined with immunotherapy is the first-line treatment in lung cancer patients. However, the 5-year survival rate is always affected by the adverse reactions and drug resistance caused by platinum-based chemotherapy. DNA damage and repair system is one of the important mechanisms that can affect the response to chemotherapy and clinical outcomes in lung cancer patients. Objective: The objective of this study is to find the relationship between the polymorphisms of DNA repair genes with the prognosis of platinum-based chemotherapy in lung cancer patients. Patients and Methods: We performed genotyping in 17 single nucleotide polymorphisms (SNPs) of Excision Repair Cross-Complementation group (ERCC) genes and X-ray Repair Cross-Complementing (XRCC) genes of 345 lung cancer patients via Sequenom MassARRAY. We used Cox proportional hazard models, state, and plink to analyze the associations between SNPs and the prognosis of lung cancer patients. Results: We found that the ERCC5 rs873601 was associated with the overall survival time in lung cancer patients treated with platinum-based chemotherapy (p = 0.031). There were some polymorphisms that were related to the prognosis in specific subgroups of lung cancer. Rs873601 showed a great influence on the prognosis of patients more than 55 years, Small Cell Lung Cancer (SCLC), and smoking patients. Rs2444933 was associated with prognosis in age less than 55 years, SCLC, metastasis, and stage III/IV/ED patients. Rs3740051 played an important role in the prognosis of SCLC and metastasis patients. Rs1869641 was involved in the prognosis of SCLC patients. Rs1051685 was related to the prognosis in non-metastasis patients. Conclusion: The ERCC5 rs873601 (G>A) was a valuable biomarker for predicting the prognosis in lung cancer patients treated with platinum-based chemotherapy.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
A Genetic Variant in ERCC2 is Associated with Gastric Cancer Prognosis in a Chinese Population

H. Chu,D. Gu,M. Xu,Z. Xu,Y. Gong,W. Gong,Y. Tang,J. Zhou,N. Tong,Z. Zhang,J. Chen,M. Wang

DOI: https://doi.org/10.1093/mutage/get023

2013-01-01

Mutagenesis

Abstract:Endogenous and exogenous factors can induce DNA damage, leading to increased risk of cancer. Nucleotide excision repair (NER) is considered as the most versatile DNA repair pathway to deal with a variety of different DNA lesions. ERCC1 and ERCC2 are the two important proteins in NER pathway. In this study, we investigated the association of three functional single nucleotide polymorphisms (SNPs) (ERCC1 rs11615, ERCC2 rs13181 and ERCC2 rs1799793) with the clinical outcome of 940 gastric cancer patients in a Chinese population. Multiplex SNaPshot technology was used to genotype these three SNPs. Our results revealed that individuals with ERCC2 rs13181TG/GG genotypes had a decreased risk of death compared with those with TT genotype [log-rank P = 0.008; adjusted hazard ratio = 0.68, 95% confidence interval = 0.51-0.91] and this protective effect was more pronounced among the subgroups of patients with tumour size ≤ 5 cm (0.59, 0.39-0.89), non-cardia gastric tumour (0.69, 0.48-0.98), no lymph node metastasis (0.55, 0.32-0.96), no distant metastasis (0.70, 0.52-0.95) and chemotherapy (0.39, 0.21-0.72). We conclude that ERCC2 rs13181 polymorphism could play different roles in the overall survival of gastric cancer. Further larger studies should be conducted to validate our findings.
Genetic Polymorphisms and Treatment Response in Advanced Non-Small Cell Lung Cancer.

Dan Su,Shenglin Ma,Peng Liu,Zhiming Jiang,Wangxia Lv,Yimin Zhang,Qinghua Deng,Stephanie Smith,Herbert Yu

DOI: https://doi.org/10.1016/j.lungcan.2006.12.002

IF: 6.081

2007-01-01

Lung Cancer

Abstract:BackgroundGenetic polymorphisms involved in DNA repair and apoptosis are suspected to influence patient response to cancer treatment. To evaluate the effect of genetic variations on chemotherapy and/or radiotherapy, we genotyped four single nucleotide polymorphisms (SNPs) in ATM (A60G), ERCC1 (Asn118Asn), APE1 (Asn148Glu), and iASPP (A67T), and examined their associations with treatment response among patients with advanced non-small cell lung cancer (NSCLC).MethodsIncluded in the study were 230 patients diagnosed with inoperable advanced NSCLC. Of these patients, 76 received platinum-based chemotherapy, 125 received chemotherapy plus radiation, and 29 received radiotherapy only. The SNPs were genotyped using the TaqMan methods.ResultsAmong the patients who received chemotherapy only, ERCC1 (Asn118Asn) genotype was significantly associated with treatment response. Patients with either one or two T alleles (T/T+C/T) at Asn118Asn were more likely not to respond to platinum-based chemotherapy compared to those without the T allele (OR=4.10, 95% CI: 1.31–12.85). For patients who were treated with both chemotherapy and radiotherapy, treatment response seemed to differ substantially between patients with different genotypes of iASPP (A67T). Patients carrying an A allele (A/T+A/A) at A67T were more likely to respond to combined chemotherapy and radiotherapy compared to those not carrying the A allele (OR=0.25, 95% CI: 0.08–0.74). An association with treatment response was also suggested for the selected polymorphism in APE1, but no association was found for the ATM polymorphism.ConclusionWe found that SNPs in ERCC1 and iASPP were associated with response to chemotherapy or combined chemotherapy and radiotherapy in NSCLC patients. These findings support the notion that genetic variations related to DNA repair or apoptosis may affect the effect of chemotherapy or radiation on NSCLC.

Drug-Induced Lipid Changes

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Nucleotide Excision Repair Gene ERCC1 19007T>C Polymorphism Contributes to Lung Cancer Susceptibility: A Meta-Analysis

Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.

Effect of ERCC2 rs13181 and rs1799793 polymorphisms and environmental factors on the prognosis of patients with lung cancer

Genetic Variants in ERCC1 and XPC Predict Survival Outcome of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Therapy

Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population.

Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression.

Association of ERCC1-C118T and -C8092A Polymorphisms with Lung Cancer Risk and Survival of Advanced-Stage Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: a Pooled Analysis Based on 39 Reports.

Single nucleotide polymorphisms in XRCC1,XPD and platinum prognosis in non-small-cell lung cancer patients

Genetic Variants in Nucleotide Excision Repair Pathway Predict Survival of Esophageal Squamous Cell Cancer Patients Receiving Platinum‐based Chemotherapy

Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients with Lung Cancer

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

Data from Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

Polymorphisms in the XRCC1 Gene Modify Survival of Bladder Cancer Patients Treated with Chemotherapy.

Single Nucleotide Polymorphism in ERCC1 118C→T Predicts the Outcome of NSCLC Patients Receiving Platinum-Based Chemotherapy

Abstract 1350: Genetic Variations in Apoptosis Pathway Are Associated with Survival in Late Stage Non-Small Cell Lung Cancer.

Association of variations in platinum resistance-related genes and prognosis in lung cancer patients

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

A Genetic Variant in ERCC2 is Associated with Gastric Cancer Prognosis in a Chinese Population

Genetic Polymorphisms and Treatment Response in Advanced Non-Small Cell Lung Cancer.